33LOW

CHM

CHIMERIC FPO [CHM]
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treatment of acute myeloid leukaemia/colorectal cancer, acute myeloid cancer, blood cancer, solid tumors, MMP2 expressing solid tumors, and CDH17 expressing solid tumors. The company was incorporated in 2020 and is based in Carlton, Australia.
Healthcare · ASX Small Cap
$0.0020 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical64
Catalyst54
Sentiment50
Fundamental6
Momentum39
Risk Gate27
Get alerts when CHM's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track CHM — Free

Active Signals

Bullish Signals

  • Beating the Small Ords index — relative strength of 1.12, so it's outpacing the pack
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is contracting — like a spring being compressed, breakouts often follow
  • Critical cash runway (1.2 quarters)
  • Low P/S ratio (0.9x)
  • Revenue in sharp decline (-53%)
  • EPS estimates revised downward (-10pts)
  • Near 52-week low (12% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (1 events)
  • Sentiment is mixed — no strong consensus either way
  • This one has been in freefall — down 50% over the past year
  • The bigger volume days are the up days — volume-weighted momentum is positive (6.46%/day)
  • Altman Z-Score distress zone (0.07 < 1.81, low-confidence approx)
  • Penny stock risk ($0.002)
  • RBA hiking (-3pts)
  • Trial readout: PHASE1 (est. 2026-05)

Risk Signals

  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (3/9, low-confidence approx)
  • Deeply negative margins (-193%)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Revenue declining at -53% — the top line is shrinking
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about CHM
"What's driving CHM's score?" "How does CHM compare to peers?" "Key risks for CHM?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

LOW Investor presentation
LOW Chimeric to present at NWR Virtual Healthcare Conference
NONE Prospectus
NONE Update - Proposed issue of securities - CHM
NONE Consolidation/Split - CHM

Recent ASX Announcements

2026-03-24 Investor presentation
2026-03-23 Chimeric to present at NWR Virtual Healthcare Conference
2026-03-22 Prospectus
2026-03-18 Update - Proposed issue of securities - CHM
2026-03-18 Consolidation/Split - CHM PRICE SENSITIVE

Key Metrics

$8.8M
Market Cap
8.4M
Avg Volume
0.9x
Vol Ratio
$0.00 — $0.01
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-1291.0%
ROE
-192.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 74%
LLeader vs LaggardlaggardRS: -4
IInstitutional SponsorshipweakInst: 4%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #115 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:CHM vs ATXCHM vs PNVCHM vs IMM
Scout Pro — Deeper Analysis for CHM
Try Pro free for 30 days
Share this analysis

Track CHM and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required